Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cyclophosphamide in Refractory Pemphigus
NCT00010413Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Apr 1999
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in pemphigus, sponsored by Johns Hopkins University. Primary endpoints: Response Rate and Event-Free Survival at 1 year. Started Apr 1999; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
pemphigus
Beyond the preview
Go deeper on NCT00010413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010413.